# Kiersten Stead > Kiersten Stead is a Series A investor at DCVC backing Biotechnology and Agriculture. See 18 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [DCVC](https://shizune.co/investors/profile/data-collective) - Location: San Francisco, United States - Total investments: 18 - Last investment: May 2026 - Lead investor: 72% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/kstead Kiersten Stead is a Series A investor at DCVC in San Francisco focused on Biotechnology and Agriculture. Kiersten Stead is based out of San Francisco, California and is the Managing Partner of DCVC. Kiersten previously worked at Monsanto Growth Ventures as an Investment Director. Kiersten Stead attended the University of Alberta. ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Biotechnology | 9 | 50% | | Agriculture | 5 | 28% | | Therapeutics | 4 | 22% | | Medical | 3 | 17% | | Health Care | 3 | 17% | 25 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series A | 12 | 67% | | Series B | 3 | 17% | | Seed | 1 | 6% | ### Country | Country | Investments | Share | | --- | --- | --- | | United States | 11 | 61% | | Canada | 1 | 6% | | Estonia | 1 | 6% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Latus Bio | Latus Bio focuses on developing innovative gene therapy candidates using precision delivery to enhance the lives of patients. Latus identified proprietary AAV capsids for clinical use. The company plans to administer low doses of its product candidates, aiming to improve clinical safety and manufacturing. | $43M | Series A | May 04, 2026 | | | Grove Biopharma | Grove Biopharma is a biotechnology company offering a materials science solution to peptide therapeutic challenges, focused on the discovery and development of a novel class of “protein-like polymers” to treat significant unmet medical needs in chronic inflammatory and neurodegenerative diseases. | $30M | Series A | Apr 23, 2025 | | | Latus Bio | Latus Bio focuses on developing innovative gene therapy candidates using precision delivery to enhance the lives of patients. Latus identified proprietary AAV capsids for clinical use. The company plans to administer low doses of its product candidates, aiming to improve clinical safety and manufacturing. | $54M | Series A | May 02, 2024 | | | Elo Life Systems | Elo Life Systems is a biotechnology company that focuses on human health and wellness through food. The company is driven by a mission to improve human health and wellness by bridging the gap between food, agriculture, and health. Elo partners with stakeholders in the food systems value chain to bridge gaps and meet needs across agriculturalproductivity, nutritional demand, food security, and human wellness. | $20.5M | Series A | Jan 24, 2024 | | | Totus Medicines | Totus Medicines uses revolutionary chemical biology to create life-changing therapies to treat previously untreatable diseases across the entire human genome. | $66M | Series B | Dec 15, 2023 | | | Novome Biotechnologies | Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered MicrobialMedicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications. | $43.5M | Series B | Sep 13, 2022 | | | Creyon Bio | Creyon Bio is a pre-clinical stage company reimagining drug development as it should be, using a data-first approach for generating uniquely powerful datasets and developing machine learning models to uncover the engineering principles that make precision oligonucleotide-based medicines possible for patient populations of all sizes. | $40M | Series A | Mar 08, 2022 | | | Plexium | Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases. Plexium's platform focuses on the discovery of next-generation TPD drugs that extend beyond the limited applications of Proteolysis Targeting Chimeras (PROTACs) and cereblon imids, unraveling the boundless possibilities of truedrug-like protein degraders. From molecular glues to monovalent degraders, the possibilities are endless across a wide variety of therapeutic areas. | $102M | Series B | Feb 23, 2022 | | | Novome Biotechnologies | Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered MicrobialMedicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications. | $33M | Series A | Jan 07, 2020 | | | Plexium | Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases. Plexium's platform focuses on the discovery of next-generation TPD drugs that extend beyond the limited applications of Proteolysis Targeting Chimeras (PROTACs) and cereblon imids, unraveling the boundless possibilities of truedrug-like protein degraders. From molecular glues to monovalent degraders, the possibilities are endless across a wide variety of therapeutic areas. | $28M | Series A | Oct 17, 2019 | | 10 of 18 investments shown. ## Co-investors - [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 4 deals together - [Leaps by Bayer](https://shizune.co/investors/profile/leaps-by-bayer) — VC Fund, 3 deals together - [5AM Ventures](https://shizune.co/investors/profile/5am-ventures) — VC Fund, 2 deals together - [8VC](https://shizune.co/investors/profile/8vc) — VC Fund, 2 deals together - [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 2 deals together - [Ben Franklin Technology Partners](https://shizune.co/investors/profile/ben-franklin-technology-partners) — VC Fund, 2 deals together ## About DCVC VC Fund · San Francisco, United States Backing entrepreneurs using Deep Tech to solve trillion-dollar problems. 5 contacts available at DCVC. | Name | Title | Profile | | --- | --- | --- | | Alan Cohen | Partner | https://shizune.co/investors/profile/alan-cohen | | Gloria Lau | Equity Partner | https://shizune.co/investors/profile/gloria-lau | | Kiersten Stead | Co-Founder | https://shizune.co/investors/profile/kiersten-stead | | Matt Trevithick | Partner | https://shizune.co/investors/profile/matt-trevithick | | Scott James | General Counsel | https://shizune.co/investors/profile/scott-james-2 | ## Similar investors ### Similar stage - [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund ## FAQ ### What does Kiersten Stead invest in? Kiersten Stead invests primarily in Biotechnology, Agriculture and Therapeutics startups, most often at Series A and Series B stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Kiersten Stead last invest? The most recent investment recorded for Kiersten Stead closed in May 2026. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co